Karo Bio and 4D Science enters research collaboration on fibrotic diseases.
The two companies will develop novel treatments for fibrotic diseases, based on a recent discoveries made by Dr. Jörg Distler. His research group has recently discovered that a specific nuclear receptor plays a key role in the pathogenesis of fibrotic diseases. The findings may be of therapeutic benefit to patients suffering from such diseases. There are currently no effective treatments of fibrosis available.
“We look forward to collaborating with Jörg Distler and his team on this novel approach to fibrosis. This is an area with very large unmet medical needs and where new ideas up until now have been scarce. Together, we will be able to speed up the development of the project significantly,” says Karo Bio’s CEO Per Bengtsson.
4D Science GmbH is a biotechnology company founded by Dr. Jörg Distler at the University of Erlangen-Nuremberg.
The collaboration will initially focus on generating additional data further validating the nuclear receptor as a target in fibrosis and demonstrating its druggability. Karo Bio will carry out the collaboration work within the scope of its current operations. The two parties will share costs and rewards for the collaboration program.